
Releases
MindWalk Holdings Prepares Q4 Results Amidst AI-Driven Growth Push
MindWalk Holdings, the Austin-based firm formerly known as ImmunoPrecise Antibodies, enters a critical earnings window on July 22, 2026. Following its recent inclusion in the Russell 3000E Index and a strategic shift toward AI-designed therapeutics, the company faces investor scrutiny over its proprietary biological data architecture and GLP-1 program trajectory.



























